TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03949868

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active control
Description: Participants in the active control group will receive 2 text messages per day for six days (one at 9am and one at 8pm) asking them to report on the activity they are currently engaged in.
Study: NCT02207543

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical telephone contact
Description: Evaluations will be conducted by telephone 15 days after hospital discharge, 30 days and then every month until 6 months.
Study: NCT02309658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: Patients received intravenous 500-1000 ml normal saline and antiemetic medication before chemotherapy. Treatment consisted of intravenous gemcitabine at a dose of 1000 mg/m2 diluted in 500 ml of normal saline administered over 30 minutes mg/m2 diluted in 500 ml of normal saline administered over 30 minutes on days 1 and 8, followed by cisplatin 35 mg/m2 administered over 2 hours on day 1 and 8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 35 mg/m2 administered over 2 hours on day 1 and 8.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: chemoradiation
Description: external beam radiotherapy concomitant with weekly cisplatin 40mg/m2
Study: NCT04256278

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Spermotrend
Description: oral administration of antioxidants for three months

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spermotrend
Description: oral administration of antioxidants for three months
Study: NCT05555719

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PowerScope Appliance
Description: PowerScope Appliance was installed on fixed orthodontic appliance
Study: NCT00465972

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxepin
Description: Doxepin 10 mg po nightly x duration of study length OR Temazepam 15 mg po nightly x duration of study length OR Placebo nightly x duration of study length

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temazepam
Description: Temazepam capsule 15 mg po nightly x duration of study

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule nightly for duration of study
Study: NCT03679676

Intervention type: DRUG
Group type: OTHER
Intervention: Omalizumab
Description: Omalizumab is injected every 2 to 4 weeks

Intervention type: DRUG
Group type: OTHER
Intervention: Omalizumab
Description: Omalizumab is injected every 2 to 4 weeks

Intervention type: DRUG
Group type: OTHER
Intervention: Dupilumab
Description: Dupilumab is injected every 2 weeks~combination, or placebo.
Study: NCT01022151

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxapram 1 mg/kg [group D]
Description: receive intravenous injection of 0.2 mL/kg of doxapram 5 mg/mL \[group D\]. All study solutions were injected within 1 min at T0 after discontinuation of sevoflurane. No stimulation was applied to patients during this period.
Study: NCT02394327

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 7-Fr Pigtail type naso-cholecystic drainage tube (Liguory nasal biliary drainage set; Wilson-Cook Medical, Salem, NC, USA)
Description: Endoscopic
Study: NCT04215848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide/Formoterol Fumarate 160 MCG-4.5 MCG Inhalation Powder
Description: After the patients who have all criteria, they will be randomized to take Budesonide/formoterol (160/4.5 μg/d) as need when they have symptoms.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide 200Mcg Inhalation Powder
Description: After the patients who have all criteria, they will be randomized to take Budesonide (200 μg) twice daily
Study: NCT04832126

Intervention type: GENETIC
Intervention: Genetic analysis
Description: Genomic DNA will be purified from peripheral blood or mouth swabs. Whole blood will be collected by peripheral phlebotomy in tubes containing K2EDTA as an anticoagulant. Blood samples will be stored at 4-8 oC for up to a week before DNA purification. Mouth swabs will be collected using the ORAcollect • DNA kit (OCR-100) (DNA Genotek Inc., Canada). Genomic DNA from whole blood or mouth swab samples will be purified using DNeasy Blood \& Tissue Kit (QIAGEN).

Intervention type: GENETIC
Intervention: Genetic analysis
Description: Genomic DNA will be purified from peripheral blood or mouth swabs. Whole blood will be collected by peripheral phlebotomy in tubes containing K2EDTA as an anticoagulant. Blood samples will be stored at 4-8 oC for up to a week before DNA purification. Mouth swabs will be collected using the ORAcollect • DNA kit (OCR-100) (DNA Genotek Inc., Canada). Genomic DNA from whole blood or mouth swab samples will be purified using DNeasy Blood \& Tissue Kit (QIAGEN).
Study: NCT00324649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Truvada
Description: Truvada once daily with continuation of the current NNRTI or PI at randomization.
Study: NCT03679676

Intervention type: DRUG
Group type: OTHER
Intervention: Dupilumab
Description: Dupilumab is injected every 2 weeks~combination, or placebo.

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Placebo is injected every 2 to 4 weeks

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Placebo is injected every 2 to 4 weeks
Study: NCT04892719

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Fluoroscopic chest imaging with 4Dx technology software analysis
Description: 4DxV utilizes a novel software algorithm to analyze data from cinefluoroscopy images to calculate regional ventilation and pulmonary function changes. Cinefluorography uses a fluorescent screen with X-rays to make real-time moving images the lung described below. This is the same x-ray fluoroscopy that is used in clinical imaging and the fluoroscopic imaging time is approximately 1 minute leading to an effective radiation dose of 2 mSv (200 mRem). This is significantly lower that the radiation exposure from a standard chest CT. Fluoroscopy images are acquired at each of five views for approximately enough time to capture at least one complete, continuous breath. The subject is required to remain in the same position for each of the five fluoroscopy imaging sequences. These images will be analyzed by the novel 4Dx technology to provide the 4Dx lung function analysis report.
Study: NCT00808522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hCG
Description: recombinant hCG subcutaneous injections x 30 doses every other day lasting 60 days total.

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: hCG
Description: recombinant hCG subcutaneous injections x 30 doses every other day lasting 60 days total.
Study: NCT01465438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Adalimumab 40 mg every other week
Study: NCT02870985

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary Stent

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coronary Stent
Study: NCT01552837

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Seroquel
Description: for 4 weeks, 300 - 800 mg per day in 2 doses
Study: NCT00436436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: O6-benzylguanine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Study: NCT04093960

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus plantarum PS128
Description: 10 mg qd of escitalopram qd plus 300mg bid of Lactobacillus plantarum PS128 to enhance antidepressive effect

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum PS128
Description: 10 mg qd of escitalopram qd plus 300mg bid of Lactobacillus plantarum PS128 to enhance antidepressive effect
Study: NCT03215381

Intervention type: DRUG
Group type: OTHER
Intervention: [11C]AZD1390
Description: \[11C\]AZD1390
Study: NCT00837161

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Philips MR guided HIFU system
Description: HIFU is the use of focused ultrasound energy to penetrate through soft tissue and causes localized high temperatures (55°C to 70°C) for a few seconds within the target producing well defined regions of protein denaturation, irreversible cell damage, and coagulative necrosis
Study: NCT02398201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bezafibrate
Description: Bezafibrate 200mg-600mg three times daily for 12 weeks.
Study: NCT03455894

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DETECT'CHUTE CLINIBED
Description: The DETECT'CHUTE carpets will be positioned at night at the foot of the bed and set in motion by the nursing staff as soon as the elderly person goes to bed for the night. They will be withdrawn the next morning after the resident's rise. Each patient will benefit from the mat for 1 month.
Study: NCT00790582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lithium carbonate
Description: The dosage of lithium carbonate will be adjusted for each individual. The maximum dose is 450mg/day.
Study: NCT01198574

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iron group
Description: Ferrous fumarate, 60 mg, weekly dose

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin A group
Description: Retinol, weekly dose, 15,000 IU

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iron and vitamin A group
Description: Ferrous fumarate, Retinol combination group, weekly dose

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo group
Description: folic acid only as placebo group
Study: NCT03538886

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting (CABG)
Description: Revascularization of LAD lesion by CABG

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous coronary intervention (PCI)
Description: Revascularization of LAD lesion by PCI
Study: NCT02494635

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Biomarker analysis
Study: NCT02394327

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 7-Fr double pigtail plastic stent (Zimmon; Wilson-Cook Medical, Salem, NC, USA)
Study: NCT01002404

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: angled and straight tipped guide wire
Description: Angled or straight tipped guide wire is used in the beginning of deep biliary cannulation in ERCP . If there is no success, other normal procedures (e.g. double wire cannulation and precut) are performed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: angled and straight tipped guide wire
Description: Angled or straight tipped guide wire is used in the beginning of deep biliary cannulation in ERCP . If there is no success, other normal procedures (e.g. double wire cannulation and precut) are performed.
Study: NCT00324649

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zidovudine/lamivudine
Description: Continuation of the zidovudine + lamivudine containing regimen plus the current NNRTI or PI at randomization.
Study: NCT04425538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: Either infliximab or infliximab-abda will be used at the discretion of the investigator
Study: NCT00250796

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thalidomide, alpha interferon
Description: If the patient SSR status is negative, patients will not be given subcutaneous injections of octreotide (Sandostatin LAR) but will receive the thalidomide and alfa interferon only.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide, interferon, Octreotide
Description: If SSR status is positive or unknown, patients will receive oral doses of thalidomide starting at 200mg a day and increasing to 800mg at increments of 200 per week depending on tolerance. They will also receive injections three times a week of alpha interferon and monthly injections of octreotide (Sandostatin LAR) 30 mg into their buttocks muscle..
Study: NCT01434186

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching with Saxagliptin
Description: Tablet, Oral, 0.0 mg, Daily, Day 1 through week 52

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin IR
Description: Tablet, Oral, 1000 mg -2000 mg, Daily , Day 1 through week 52

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin IR
Description: Tablet, Oral, 1000 mg -2000 mg, Daily , Day 1 through week 52

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin XR
Description: Tablet, Oral, 1000 mg -2000 mg, Daily, Day 1 through week 52

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin XR
Description: Tablet, Oral, 1000 mg -2000 mg, Daily, Day 1 through week 52

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: Saxagliptin Tablet, 2.5 mg, or Saxagliptin Tablet, 5 mg, (based on subject's weight)
Study: NCT00663767

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo; oral
Description: dose 1, dose 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo; oral
Description: dose 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARRY-371797, p38 inhibitor; oral
Description: dose 1: multiple dose levels

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARRY-371797, p38 inhibitor; oral
Description: dose 1: multiple dose levels; dose 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib, COX-2 inhibitor; oral
Description: dose 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib, COX-2 inhibitor; oral
Description: dose 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo; oral
Description: dose 2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo; oral
Description: dose 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARRY-371797, p38 inhibitor; oral
Description: dose 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARRY-371797, p38 inhibitor; oral
Description: dose 2
Study: NCT01330771

Intervention type: DRUG
Intervention: hMG-HP/r-FSH
Study: NCT04588714

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resilience-based, Energy Management to Enhance Wellbeing (RENEW)
Description: The program includes unlimited website access and 10 scheduled phone calls with an assigned peer mentor.
Study: NCT02287207

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial direct current stimulation (tDCS)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial direct current stimulation (tDCS)
Study: NCT03668561

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Caligaloc
Description: 15 days of wearing of the Caligaloc orthosis
Study: NCT02551432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab, paclitaxel
Description: pembrolizumab, paclitaxel
Study: NCT04339322

Intervention type: OTHER
Intervention: Follow up
Description: Follow up to assess the outcome until complications, improvement, death or being transferred to another quarantine hospital.
Study: NCT02343419

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Methacholine Challenge Test
Description: Forced oscillation technique test, plethysmography, interrupter technique test and spirometry will be performed in a row before any intervention and after inhalation of aerosols - normal saline, followed by increasing concentrations of methacholine: 0.03 mg/ml; 0.06 mg/ml; 0.125 mg/ml; 0.25 mg/ml, 0.5 mg/ml, 1 mg/ml, 2 mg/ml, 4 mg/ml, 8 mg/ml, 16 mg/ml.~In case of FEV1 decrease of ≥ 20% of the initial value methacholine challenge test will be ceased and patient will be administered 200 µg of salbutamol in inhalation. Then, pulmonary function tests will be performed after 15 minutes.
Study: NCT03449121

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Slow breathing techniques
Description: 8 sessions of instruction in slow breathing exercises over 12 weeks of study
Study: NCT03119246

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CAPIT-HD beta
Description: New assessment protocol for assessment of complex therapies in Huntington's disease for both groups

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CAPIT-HD beta
Description: New assessment protocol for assessment of complex therapies in Huntington's disease for both groups
Study: NCT04103775

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation
Description: See Cognitive Remediation Arm description.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Control
Description: See Active Control Arm description.
Study: NCT04213937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: Drug: nab-paclitaxel 125mg/m2, i.v. d1, d8, Repeated every 3 weeks for 4-6 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topotecan
Description: Drug: Topotecan 1.25mg/m2/d, i.v, 1hour, d1-d5, Repeated every 3 weeks for 4-6 cycles.
Study: NCT03613844

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for DHA
Study: NCT04718298

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ProFlor laparoscopic technique
Description: Inguinal hernia repair laparoscopic
Study: NCT00702039

Intervention type: OTHER
Intervention: No Music
Description: No music will be played in patients in arm 2 of the study.

Intervention type: OTHER
Intervention: Music Therapy
Description: Classical music being played during intravitreal injection.
Study: NCT01968759

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevelamer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevelamer
Study: NCT04580212

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Poultry hygiene intervention
Description: The intervention will consist of a series of participatory training exercises designed to accomplish three main goals: (1) increase awareness of health risks and lost livelihood benefits of current poultry management practices, (2) build practical skills for poultry management, and (3) build supportive community norms by facilitating savings group discussions on poultry management. The intervention will be delivered through three activities: (1) triggering exercise designed to raise awareness of both the health risks of the current practices and the economic potential of a more active poultry management approach, and ultimately to motivate participants for behavior change, (2) poultry management training activity based on local needs and norms, and (3) periodic follow-on coaching to reinforce messages from the initial training and emphasize action planning, monitoring of plan execution, and troubleshooting.
Study: NCT04219488

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radial nerve mobilization
Study: NCT01968759

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramipril and Irbesartan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramipril and Irbesartan
Study: NCT01881347

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resveratrol
Description: Resveratrol 100 mg daily for 2 weeks followed by resveratrol 300 mg daily for 2 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resveratrol
Description: Resveratrol 100 mg daily for 2 weeks followed by resveratrol 300 mg daily for 2 weeks.
Study: NCT04219488

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supervised home program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervised home program
Study: NCT03384628

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: First pair Senofilcon A contact lens
Description: Fit assessment of the first pair contact lenses.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Second pair Senofilcon A contact lens
Description: Fit assessment of the second pair of contact lenses.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Third pair Senofilcon A contact lens
Description: Fit assessment of the third pair of contact lenses.
Study: NCT00265967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irbesartan
Description: Irbesartan 150-300 mg/d for 8 weeks
Study: NCT01798017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone and misoprostol
Description: Women will receive 200mg mifepristone followed in 24-48h by 800mcg bucccal misoprsotol
Study: NCT04137562

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ADSTEM Inj.
Description: Two 5mL of the following study drug is pre-mixed with 320mL of 0.9% normal saline is injected intravenously twice for the duration of the study. Treatment group: ADSTEM Inj. 0.5x10\^8 cells/5mL
Study: NCT01881347

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo 100 mg daily for 2 weeks followed by placebo 300 mg daily for 2 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo 100 mg daily for 2 weeks followed by placebo 300 mg daily for 2 weeks.
Study: NCT04137562

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 330mL of 0.9% normal saline is injected intravenously twice for the duration of the study.
Study: NCT02823080

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetrorelix
Description: study group received 3-day Cetrorelix Acetate sc injection (0.25 mg/day) started on Day-0. Serum E2, pain scores and MOD were checked daily. Hematocrit value (Ht%), total leucocytic count (TLC), gastrointestinal (GI) manifestations and ascites control (24 patients) did not receive Cetrorelix Acetate. Grading were re-evaluated on Day-3, 6 and 8.
Study: NCT00943085

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family-focused therapy
Description: 12 therapy sessions involving the at-risk child or adolescent, parents, and available siblings. Therapy will include psychoeducation about mood disorders, communication enhancement training, and problem-solving skills training. Ongoing medication management from a study psychiatrist will be available.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief educational treatment
Description: Thorough diagnostic assessment by a study evaluator, separate evaluation by a child psychiatrist, feedback session with parents and child, and provision of reading materials pertinent to managing childhood mood disorders. Ongoing medication management and crisis-oriented family sessions will be available as needed.
Study: NCT01925391

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tono-pen XL Applanation tonometer + Ocu-film +
Study: NCT04234750

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mesenchymal stem cell conditioned medium-derived pleiotropic factor
Description: After the patient is enrolled, when the patient's condition is stable, he is ready to undergo skin transplantation. For the donor site, an electric dermatome was used to remove the skin. The two donor areas of the same patient were divided into a pleiotropic factor group and a blank group randomly. After placing a coarse mesh vaseline oil gauze, then cover a certain thickness of sterile gauze and pressure bandage.